Gilead Sciences (GILD) Selling, General & Administrative (2009 - 2026)
Powered by 
Analysis
Gilead Sciences (GILD) Selling, General & Administrative (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 1.75 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 1.92 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 582.20 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 662.10 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | -417.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 216.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 709.70 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 165.53 Mn |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | 247.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.92 Bn |
| Mar 31, 2026 | 1.45 Bn |
| Dec 31, 2025 | 1.79 Bn |
| Sep 30, 2025 | 1.36 Bn |
| Jun 30, 2025 | 1.37 Bn |
| Mar 31, 2025 | 1.26 Bn |
| Dec 31, 2024 | 1.91 Bn |
| Sep 30, 2024 | 1.43 Bn |
| Jun 30, 2024 | 1.38 Bn |
| Mar 31, 2024 | 1.38 Bn |
| Dec 31, 2023 | 1.61 Bn |
| Sep 30, 2023 | 1.32 Bn |
| Jun 30, 2023 | 1.85 Bn |
| Mar 31, 2023 | 1.32 Bn |
| Dec 31, 2022 | 406.00 Mn |
| Sep 30, 2022 | 1.21 Bn |
| Jun 30, 2022 | 1.36 Bn |
| Mar 31, 2022 | 1.08 Bn |
| Dec 31, 2021 | 1.65 Bn |
| Sep 30, 2021 | 1.19 Bn |